359 related articles for article (PubMed ID: 38276976)
1. The pivotal role of long non-coding RNAs as potential biomarkers and modulators of chemoresistance in ovarian cancer (OC).
Malgundkar SH; Tamimi Y
Hum Genet; 2024 Feb; 143(2):107-124. PubMed ID: 38276976
[TBL] [Abstract][Full Text] [Related]
2. HER2 puzzle pieces: Non-Coding RNAs as keys to mechanisms, chemoresistance, and clinical outcomes in Ovarian cancer.
Yang F; Yan L; Ji J; Lou Y; Zhu J
Pathol Res Pract; 2024 Jun; 258():155335. PubMed ID: 38723327
[TBL] [Abstract][Full Text] [Related]
3. Long non-coding RNAs in recurrent ovarian cancer: Theranostic perspectives.
Bhardwaj V; Tan YQ; Wu MM; Ma L; Zhu T; Lobie PE; Pandey V
Cancer Lett; 2021 Apr; 502():97-107. PubMed ID: 33429007
[TBL] [Abstract][Full Text] [Related]
4. Role of lncRNAs as Novel Biomarkers and Therapeutic Targets in Ovarian Cancer.
Fu LL; Li CJ; Xu Y; Li LY; Zhou X; Li DD; Chen SX; Wang FG; Zhang XY; Zheng LW
Crit Rev Eukaryot Gene Expr; 2017; 27(2):183-195. PubMed ID: 28845767
[TBL] [Abstract][Full Text] [Related]
5. A novel risk score system for assessment of ovarian cancer based on co-expression network analysis and expression level of five lncRNAs.
Zhao Q; Fan C
BMC Med Genet; 2019 Jun; 20(1):103. PubMed ID: 31182053
[TBL] [Abstract][Full Text] [Related]
6. The Regulatory Roles of Long Non-Coding RNA in the Chemoresistance Process of Ovarian cancer.
Qu J; Kamal MA; Yuan C
Curr Pharm Des; 2019; 25(8):856-861. PubMed ID: 30947657
[TBL] [Abstract][Full Text] [Related]
7. Long non-coding RNAs in ovarian cancer.
Zhan L; Li J; Wei B
J Exp Clin Cancer Res; 2018 Jun; 37(1):120. PubMed ID: 29921308
[TBL] [Abstract][Full Text] [Related]
8. Long Non-Coding RNAs: the New Horizon of Gene Regulation in Ovarian Cancer.
Worku T; Bhattarai D; Ayers D; Wang K; Wang C; Rehman ZU; Talpur HS; Yang L
Cell Physiol Biochem; 2017; 44(3):948-966. PubMed ID: 29179183
[TBL] [Abstract][Full Text] [Related]
9. The underlying mechanisms of non-coding RNAs in the chemoresistance of pancreatic cancer.
Xiong G; Feng M; Yang G; Zheng S; Song X; Cao Z; You L; Zheng L; Hu Y; Zhang T; Zhao Y
Cancer Lett; 2017 Jul; 397():94-102. PubMed ID: 28254409
[TBL] [Abstract][Full Text] [Related]
10. Noncoding RNAs Interplay in Ovarian Cancer Therapy and Drug Resistance.
Liu M; Zhang H; Li Y; Wang S
Cancer Biother Radiopharm; 2022 Apr; 37(3):186-198. PubMed ID: 35133881
[TBL] [Abstract][Full Text] [Related]
11. In Silico screening of circulating tumor DNA, circulating microRNAs, and long non-coding RNAs as diagnostic molecular biomarkers in ovarian cancer: A comprehensive meta-analysis.
Zhang L; Hu C; Huang Z; Li Z; Zhang Q; He Y
PLoS One; 2021; 16(4):e0250717. PubMed ID: 33901236
[TBL] [Abstract][Full Text] [Related]
12. The Role of Long Non-Coding RNAs in Ovarian Cancer.
Nikpayam E; Tasharrofi B; Sarrafzadeh S; Ghafouri-Fard S
Iran Biomed J; 2017 Jan; 21(1):3-15. PubMed ID: 27664137
[TBL] [Abstract][Full Text] [Related]
13. Multidrug resistant lncRNA profile in chemotherapeutic sensitive and resistant ovarian cancer cells.
Xu J; Wu J; Fu C; Teng F; Liu S; Dai C; Shen R; Jia X
J Cell Physiol; 2018 Jun; 233(6):5034-5043. PubMed ID: 29219179
[TBL] [Abstract][Full Text] [Related]
14. Long non-coding RNAs (lncRNAs) signaling in cancer chemoresistance: From prediction to druggability.
Eptaminitaki GC; Stellas D; Bonavida B; Baritaki S
Drug Resist Updat; 2022 Dec; 65():100866. PubMed ID: 36198236
[TBL] [Abstract][Full Text] [Related]
15. Profile and validation of dysregulated long non‑coding RNAs and mRNAs in ovarian cancer.
Lu YM; Wang Y; Liu SQ; Zhou MY; Guo YR
Oncol Rep; 2018 Nov; 40(5):2964-2976. PubMed ID: 30132558
[TBL] [Abstract][Full Text] [Related]
16. Integrated clinical characteristics and omics analysis identifies a ferroptosis and iron-metabolism-related lncRNA signature for predicting prognosis and therapeutic responses in ovarian cancer.
Feng S; Yin H; Zhang K; Shan M; Ji X; Luo S; Shen Y
J Ovarian Res; 2022 Jan; 15(1):10. PubMed ID: 35057848
[TBL] [Abstract][Full Text] [Related]
17. Diagnostic value of non-coding RNAs in ovarian cancer.
Sun N; Liu S; Chen A
J Obstet Gynaecol; 2022 Nov; 42(8):3416-3423. PubMed ID: 36476021
[TBL] [Abstract][Full Text] [Related]
18. Upregulation of the long non-coding RNA SPRY4-IT1 indicates a poor prognosis and promotes tumorigenesis in ovarian cancer.
Li H; Liu C; Lu Z; Chen L; Wang J; Li Y; Ma H
Biomed Pharmacother; 2017 Apr; 88():529-534. PubMed ID: 28129625
[TBL] [Abstract][Full Text] [Related]
19. LncRNAs Roles in Chemoresistance of Cancer Cells.
Taghvimi S; Abbaszadeh S; Banan FB; Fard ES; Jamali Z; Najafabadi MA; Savardashtaki A; Movahedpour A
Curr Mol Med; 2022; 22(8):691-702. PubMed ID: 34711162
[TBL] [Abstract][Full Text] [Related]
20. miRNA and long non-coding RNA: molecular function and clinical value in breast and ovarian cancers.
Panoutsopoulou K; Avgeris M; Scorilas A
Expert Rev Mol Diagn; 2018 Nov; 18(11):963-979. PubMed ID: 30338716
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
